6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Menjugate: new trials by email Literature Review of Menjugate trials Research Report on Menjugate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa Blood sampling, Malaria Vaccine 257049 (MALARIA-055 PRI), Meningococcal C Conjugate Vaccine (MALARIA-055 PRI) - Malaria | Phase 3 | Completed | GlaxoSmithKline | 3084 | 2014-09-18 | 2019-11-25 |
| Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®, Meningococcal Group C Conjugate vaccine: MenC - Meningitis, Meningococcal Infection | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 123 | 2011-05-01 | 2016-08-19 |
| Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children Nimenrix (GSK134612 vaccine), Menjugate - Infections, Meningococcal, Meningococcal Vaccines | Phase 3 | Completed | GlaxoSmithKline | 271 | 2011-01-03 | 2020-11-23 |
| Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine - Malaria | Phase 3 | Completed | GlaxoSmithKline | 15459 | 2009-03-27 | 2019-10-09 |
| Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children GSK Biologicals' meningococcal vaccine GSK134612, Menjugate - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 414 | 2008-05-09 | 2019-11-18 |
| Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1), Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2), Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) - Serogroup B Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 3630 | 2008-03-01 | 2017-10-10 |
Meningococcal Infections (4) · Malaria (2) · Malaria, Falciparum (1) · Meningitis (1) · Meningitis, Meningococcal (1)
GlaxoSmithKline (4) · Novartis Vaccines (1) · Sanofi Pasteur, a Sanofi Company (1)
Germany (3) · Burkina Faso (2) · France (2) · Kenya (2) · Tanzania (2) · Austria (1) · Canada (1) · Czechia (1) · Finland (1) · Gabon (1) · Ghana (1) · Italy (1) · Malawi (1) · Mozambique (1)
PMID 23324563, PMID 24565019, PMID 25285126, PMID 26702637, PMID 28470856, PMID 29179625, PMID 29756531, PMID 31110098, PMID 31708182, PMID 32532234, PMID 33509156, PMID 35060479, PMID 36578806, PMID 37790581, PMID 38115002